Home Liquid Biopsy and ctDNA ctDNA Minimal Residual Disease (MRD) Test: Recurrence Risk, Tumor DNA Monitoring, and...

ctDNA Minimal Residual Disease (MRD) Test: Recurrence Risk, Tumor DNA Monitoring, and Meaning

By
Vita Library
-
3
Learn what a ctDNA MRD test means, how tumor-informed and tumor-naive testing differ, and how positive or negative results relate to cancer recurrence risk.

A ctDNA minimal residual disease (MRD) test looks for tiny amounts of tumor-derived DNA in blood after treatment has removed or destroyed all cancer that can be found by standard methods. In solid tumors, the terms molecular residual disease and measurable residual disease are also used. A positive ctDNA MRD result is strongly associated with a higher risk that cancer will later recur, often before recurrence can be seen on routine imaging. A negative result is more favorable, but it does not prove that every cancer cell is gone because very small or low-shedding disease can escape detection. MRD tests may be tumor-informed, using mutations selected from a patient’s tumor, or tumor-naive, using a fixed blood-based approach. The result is most useful when the oncology team knows what evidence-based action should follow, because the role of MRD-guided treatment differs by cancer type, stage, assay, and clinical setting.

  • ctDNA-positive MRD after curative-intent treatment usually means a substantially higher recurrence risk than ctDNA-negative status.
  • A negative MRD test lowers risk but does not reduce recurrence risk to zero because test sensitivity is imperfect.
  • Tumor-informed and tumor-naive assays are different strategies and should not be compared as if they measure exactly the same thing.
  • Serial testing can improve detection compared with one postoperative blood draw and may identify molecular relapse before imaging.
  • A positive result should lead to a cancer-specific plan, not an automatic assumption that more treatment is always beneficial.

Table of Contents

What ctDNA MRD Means After Cancer Treatment

In solid tumors, minimal residual disease refers to cancer that remains after treatment but is too small to be detected by conventional imaging or routine clinical examination. The word “minimal” describes the amount of detectable disease, not its biological importance. A few remaining cancer cells can eventually grow into a visible recurrence.

ctDNA MRD testing tries to find molecular evidence of that hidden disease. Tumor cells release fragments of DNA into body fluids, including blood. After a tumor has been removed or treated, a sufficiently sensitive assay may detect tumor-associated DNA even when scans show no evidence of disease.

This is different from a standard ctDNA test used to profile advanced cancer. Broad genomic tests may look across many genes to find treatment targets. MRD assays are designed to detect extremely low levels of residual tumor signal, sometimes by tracking a small group of patient-specific mutations at very high sensitivity.

MRD is also different from radiographic recurrence. A person can have a positive MRD test while CT, MRI, or PET imaging remains negative. This state is sometimes called molecular recurrence. The blood test may be detecting disease at a stage below the size threshold that imaging can reliably visualize.

The clinical importance comes from prognosis. Across many resectable solid tumors, postoperative or post-treatment ctDNA positivity has been consistently associated with a much higher chance of recurrence. A 2024 systematic review and meta-analysis of 80 prospective studies found that ctDNA-positive patients had a pooled recurrence hazard more than seven times that of ctDNA-negative patients. That is a group-level association, not a personal prediction of exactly when recurrence will happen.

MRD testing is most mature in cancers such as colorectal cancer, and substantial research also involves lung, breast, bladder, pancreatic, and other solid tumors. The strength of evidence and recommended actions are not identical across these diseases.

Tumor-Informed vs Tumor-Naive MRD Tests

Two broad strategies are used for ctDNA MRD: tumor-informed and tumor-naive, also called tumor-agnostic in some contexts.

A tumor-informed ctDNA test begins with the patient’s tumor tissue. The laboratory sequences the tumor, identifies mutations that appear to belong to that cancer, and then creates or selects a personalized blood assay to track those mutations over time.

Advantages can include high specificity and the ability to follow several tumor-specific variants at once. Tracking multiple known tumor variants makes it less likely that a single technical artifact will be mistaken for residual cancer. It can also help distinguish the cancer signal from unrelated mutations arising in blood cells.

The tradeoffs are practical. Tumor-informed testing usually requires adequate tumor tissue, extra setup steps, and time to build the personalized assay. If tissue is unavailable or of poor quality, the method may not be possible. A tumor may also evolve, so mutations chosen from the original specimen may not represent every future resistant clone.

A tumor-naive ctDNA test does not require prior sequencing of the patient’s tumor. Instead, it analyzes blood using a predefined set of genomic, epigenomic, or other features intended to recognize tumor-derived material.

The main advantage is speed and independence from archived tissue. This can be useful when tissue is unavailable or when a blood-first workflow is preferred. The challenge is that the assay must distinguish very weak cancer signals from normal biological background without knowing the exact molecular fingerprint of that patient’s tumor in advance.

Neither approach is automatically superior in every setting. Performance depends on the cancer type, assay design, number and type of targets, sequencing depth, error suppression, timing, and definition of a positive result. A report should be interpreted using validation data for that specific test rather than generalizing from the label “tumor-informed” or “tumor-naive.”

It is also possible for newer assays to combine mutation information with methylation, fragment patterns, or other molecular features. These multimodal approaches aim to improve sensitivity while controlling false positives, but they require their own clinical validation.

When MRD Blood Tests Are Done and How They Work

MRD testing is usually considered after treatment intended to eradicate localized cancer, such as surgery with or without chemotherapy or radiation. The exact timing is important because blood collected too soon after an operation may contain a surge of normal cfDNA from tissue injury. That extra background DNA can dilute the already tiny tumor signal.

There is no universal postoperative day that is correct for every cancer or assay. Some protocols draw the first landmark sample a few weeks after surgery, while others align testing with recovery, pathology review, or the planned start of adjuvant therapy. The laboratory and cancer-specific evidence should guide the schedule.

A typical process is:

  1. Blood is collected in a validated tube and processed to plasma.
  2. Cell-free DNA is isolated from plasma.
  3. The assay searches for the patient’s selected tumor variants or for a predefined tumor-associated signal.
  4. Statistical and error-suppression methods determine whether the signal meets the test’s threshold for MRD detection.
  5. Results are interpreted in relation to treatment timing, imaging, pathology, and prior MRD tests.

Some patients have a single landmark test at a defined time after treatment. Others undergo longitudinal testing, with samples collected every few months or at other protocol-defined intervals. Longitudinal testing can catch a tumor signal that was below the detection limit at the first draw or that emerges later as a small residual clone grows.

The 2024 meta-analysis of prospective studies found pooled sensitivity of about 50% for landmark testing and about 74% for longitudinal testing across heterogeneous cancers and assays. Those figures should not be used as the sensitivity of any one commercial test, but they illustrate why one negative sample cannot rule out microscopic disease.

MRD blood draws should ideally be compared using the same assay. Changing platforms can change the limit of detection, targets, positivity criteria, and report format. A conversion from negative to positive is more interpretable when the analytical method has remained consistent.

Treatment timing also matters. Chemotherapy, radiation, immunotherapy, and targeted therapies can change tumor shedding. A sample drawn during treatment may answer a different question from one drawn after all planned therapy is complete.

What a Positive ctDNA MRD Result Means for Recurrence Risk

A positive MRD result means the assay detected a tumor-associated molecular signal above its validated threshold after treatment. In the right setting, it indicates that residual cancer is likely present even if no tumor is visible on imaging.

The strongest and most consistent meaning is higher recurrence risk. In the 2024 meta-analysis of 80 prospective studies, ctDNA-positive status after treatment was associated with a pooled hazard ratio for recurrence of 7.48 compared with ctDNA-negative status. Overall survival was also worse in the ctDNA-positive group.

A hazard ratio is not the same as an absolute recurrence probability. It does not mean that every ctDNA-positive patient will recur, nor that recurrence risk is exactly 748%. Absolute risk depends on the underlying cancer, stage, pathology, treatment, assay, timing, and follow-up period.

The result can also have a lead time advantage. In some studies, ctDNA becomes positive months before recurrence appears on imaging. That creates an opportunity for earlier risk recognition, but earlier detection only improves outcomes if an effective intervention is available and acting on the result provides more benefit than harm.

A newly positive result after previous negative samples is often called molecular relapse or molecular recurrence. The oncology team may repeat the test to confirm the pattern, order imaging earlier, review the original pathology, or consider a clinical trial. In disease settings with supportive evidence, the result may influence systemic therapy decisions.

A persistently positive result can be more concerning than a single low-level positive sample because it suggests the tumor signal is reproducible. A rising quantitative signal may also add context in some assays. However, current guidance cautions against treating ctDNA percentages or concentrations as a universal surrogate for tumor burden. The validated positive/negative status and the clinical action associated with it are usually more important than an isolated numeric value.

The psychological impact should not be underestimated. Molecular recurrence can create anxiety precisely because the blood test may be positive before imaging can show where the disease is. Patients should be told what the result can establish, what it cannot locate, and what the next decision point will be.

What a Negative MRD Result Means

A negative or not-detected MRD result is generally favorable. It means the assay did not find a tumor signal in that blood sample at or above its detection threshold. In many studies, ctDNA-negative patients have a substantially lower recurrence rate than ctDNA-positive patients.

It does not mean the patient is guaranteed to be cured. The main reason is limited sensitivity. Residual disease may be too small to shed enough DNA, may release DNA intermittently, may be located in a site that contributes little ctDNA to plasma, or may not contain the molecular targets being tracked.

A tumor-informed assay can also miss recurrence if the residual clone no longer carries, or no longer sheds, the selected tracked variants. Tumor-naive methods have different risks, including background noise and limitations in recognizing extremely small signals.

This is why serial negative results can be more informative than one negative draw. In longitudinal monitoring, repeated absence of detectable ctDNA over time may strengthen the evidence that the patient remains in a lower-risk group. Even then, standard surveillance is usually continued unless strong trial data support reducing it.

A negative result should therefore be interpreted with conventional recurrence-risk factors. Surgical margins, lymph-node involvement, tumor stage, grade, molecular subtype, treatment response, and other pathology features remain important. MRD adds another layer of information rather than erasing the rest of the risk model.

The distinction is especially important when patients consider adjuvant therapy. A negative MRD result may identify a lower-risk group, but de-escalating or omitting established therapy requires evidence that doing so does not compromise cure. Some clinical trials are designed specifically to answer that question.

A report that says “not detected” can also be technically non-informative if the sample fails quality checks or contains too little analyzable DNA. Patients should distinguish a true negative from an inadequate or indeterminate test.

How MRD Results Can Affect Monitoring and Treatment

The central question in MRD testing is not only whether the assay predicts recurrence. It is whether using the result to make a decision improves patient outcomes.

Prognostic validity is already strong across multiple solid tumors: ctDNA-positive MRD identifies a group at higher risk. Clinical utility is a higher bar. It requires evidence that changing surveillance or treatment because of the MRD result leads to better outcomes or safely avoids unnecessary therapy.

Potential uses include:

  • Adjuvant treatment escalation: giving or intensifying treatment for a patient with positive MRD who appears at unusually high risk.
  • Treatment de-escalation: reducing or omitting therapy for selected MRD-negative patients when supported by randomized evidence.
  • Post-treatment surveillance: repeating ctDNA to detect molecular recurrence before symptoms or imaging changes.
  • Clinical-trial selection: enrolling patients with molecular residual disease into trials testing early intervention.
  • Response assessment: determining whether an initially positive MRD signal clears during or after therapy.

These uses are not equally established in every cancer. Colorectal cancer has some of the most developed randomized evidence for ctDNA-guided adjuvant strategies, while other cancers remain more investigational or have narrower indications.

The 2026 ASCO ctDNA guideline takes a decision-focused approach: outside tumor-genotyping uses, ctDNA testing may be offered when a specific evidence-based action can be taken with the result or when it can resolve conflict or ambiguity in standard assessment. This framing is important because simply finding recurrence earlier is not enough if there is no proven beneficial action.

A positive MRD result may trigger earlier imaging, but ctDNA usually cannot show the anatomical location of recurrence. If imaging remains negative, the team may continue close monitoring rather than repeatedly performing invasive procedures without a clear target.

Similarly, a negative result should not automatically cancel guideline-recommended imaging or follow-up. The test works best as part of an integrated surveillance strategy.

Patients considering a branded assay such as a personalized ctDNA MRD test should ask whether the specific test has validated performance and treatment-linked evidence for their cancer, not only whether it can technically detect tumor DNA.

Limitations, False Results, and Questions to Ask

MRD is analytically difficult because the target can be extraordinarily rare. After apparently successful treatment, tumor DNA may be present at only a tiny fraction of total cfDNA. Lowering the detection threshold increases sensitivity, but it also increases the challenge of separating true tumor signal from errors and unrelated biological variants.

False-negative results can occur because of low shedding, small disease volume, sample timing, limited plasma volume, assay coverage, or anatomical location. A negative result is therefore a risk marker, not proof that residual cancer does not exist.

False-positive results can come from technical noise or from clonal hematopoiesis, in which blood-forming cells acquire age-related somatic mutations. These mutations can appear in plasma even though they did not come from the solid tumor. Tumor-informed design, paired white-blood-cell sequencing, and computational filtering can reduce this problem but cannot make every assay perfect.

The original tumor itself may be heterogeneous. A small tissue sample may not capture all clones. If the MRD assay tracks only variants from one part of the tumor, a different residual clone can theoretically escape detection.

Cost, insurance coverage, access, turnaround time, and the need for tumor tissue also affect real-world use. A technically excellent assay may be less useful if the result arrives after the treatment decision has already been made.

Before testing, useful questions include:

  • Is this assay tumor-informed or tumor-naive?
  • What cancer type and treatment setting was it validated in?
  • What is the planned blood-draw schedule?
  • What does a positive result change in my care?
  • What does a negative result change, if anything?
  • Will standard imaging and follow-up continue?
  • If the result conflicts with imaging or pathology, which test will guide the next step?

After a positive result, ask whether confirmation is needed and whether there is evidence for treatment now versus closer monitoring. After a negative result, ask what recurrence risk remains and whether repeated testing adds useful information.

MRD technology is advancing rapidly, and performance can improve through deeper sequencing, methylation analysis, fragmentomics, and multi-feature models. Those advances do not remove the need for outcome trials. The key standard is not merely detecting smaller amounts of DNA, but showing that the information helps patients live longer, avoid ineffective treatment, or safely reduce unnecessary treatment.

References

Disclaimer

A ctDNA MRD result is a recurrence-risk biomarker, not a guarantee that cancer will or will not return. Test performance and the benefit of acting on the result vary by cancer type, assay, timing, and treatment setting. Decisions about additional therapy, imaging, or surveillance should be made with the oncology team using cancer-specific evidence and the complete clinical picture.

RELATED ARTICLESMORE FROM AUTHOR